Title | Unusual Presentation of Advanced Urothelial Cancer in a Young Patient. |
Publication Type | Journal Article |
Year of Publication | 2025 |
Authors | Guevara D, Shin N, Boiko A, Valiev I, Elsaeed AG, Mosquera JMiguel, Assaad MAl, Manohar J, Sigouros M, Zaichikova A, Fomchenkova V, Yunusova L, Smirnova S, Elemento O, Nanus D, Sternberg CN |
Journal | Anticancer Res |
Volume | 45 |
Issue | 2 |
Pagination | 613-618 |
Date Published | 2025 Feb |
ISSN | 1791-7530 |
Keywords | Adult, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Transitional Cell, Humans, Immunotherapy, Male, Mutation, Retinoblastoma Binding Proteins, Tumor Suppressor Protein p53, Ubiquitin-Protein Ligases, Urethral Neoplasms |
Abstract | BACKGROUND/AIM: Urothelial carcinoma, common in older adults, is rare in younger populations and even less common in the prostatic urethra. Advanced disease is typically managed with platinum-based chemotherapy, immune checkpoint inhibitors, and targeted therapies. However, rare presentations in young patients with aggressive disease highlight the need for innovative and personalized treatment strategies. CASE REPORT: This case report presents a rare instance of metastatic urothelial carcinoma originating in the prostatic urethra of a 37-year-old male. Initial symptoms led to diagnosis through imaging, biopsy, and genetic profiling, revealing mutations in TP53 and RB1. The patient underwent multiple treatments, including dose-dense chemotherapy, pembrolizumab immunotherapy, and targeted antibody-drug conjugates (Enfortumab Vedotin and Sacituzumab Govitecan). Despite aggressive therapies, disease management remained challenging, leading to experimental treatments, including a personalized vaccine. CONCLUSION: This case underscores the importance of precision medicine and the need for innovative treatment options for rare and aggressive cancers. |
DOI | 10.21873/anticanres.17448 |
Alternate Journal | Anticancer Res |
PubMed ID | 39890191 |